Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-associated skin cancer with an increasing incidence and a 5-year disease-associated mortality of 46%. Despite this growing health impact, very few clinical trials have focused on this unique disease and no targeted therapies exist. The Merkel cell polyomavirus (MCPyV), discovered in 2008, is involved in the pathogenesis of approximately 80% of MCC tumors. MCC typically requires persistent expression of immunogenic polyomavirus tumor-antigen (T-Ag) oncoproteins for growth and survival, making them ideal targets for immune therapy. Several lines of evidence suggest the importance of immune function in MCC. Patients with profound T-cell dysfunction have 10- to 30-fold increased MCC risk and their MCC sometimes spontaneously regresses following improvement in immune function. We have previously demonstrated that intratumoral CD8+ T cell infiltration is associated with excellent survival regardless of extent of disease at presentation. Although T cell immunosuppression is associated with increased MCC risk, >90% of MCC patients have no known immune suppression, suggesting a role for local immunosuppression in the tumor microenvironment. Indeed, we have recently found that most MCC tumors have prominent down-regulation of class-I HLA, a known mechanism for allowing tumor cells to escape host immunosurveillance by evading CD8+ T lymphocytes. We have shown that HLA-I down-regulation can be reversed in MCC by intratumoral interferon injection or by a single dose of radiation. Ongoing expression of viral oncoproteins combined with reversibility of immune evasion mechanisms in MCC present exciting opportunities to develop rational therapy for this often-lethal cancer. Collaborations between Drs. Nghiem, Koelle, Yee, and Chapuis have resulted in treatment of the first MCC patient with MCPyV-specific polyclonal T cells in conjunction with HLA-I up-regulating adjuvants. Responses include significant tumor shrinkage, persistence of MCPyV-specific T cells at several-fold above baseline, and improved antigen-specific T cell responses over 100 days after T cell infusion.
In Aim 1, a phase I/II trial will examine the safety and efficacy of therapy with polyclonal antiviral T cells of a desired specificity/phenotype infused following HLA-I up-regulating pre-treatment. Availability of a large panel of MCPyV peptide-HLA tetramers will allow polyclonal antiviral T cells to be expanded and then tracked in vivo. Although highly promising and currently feasible, adoptive T cell therapy is costly and patient-specific.
In Aim 2, we will develop tools and explore the potential for future """"""""off-the-shelf"""""""" recombinant T cell receptor-based therapies by creating a panel of MCPyV-specific soluble T cell receptors. These versatile tools will be used to determine the baseline and induced expression of viral peptide/HLA complexes on MCC cells and could be readily developed into tumor-targeted delivery vehicles for stimulatory cytokines, radioactivity emitters, or emerging therapeutics.

Public Health Relevance

Merkel cell carcinoma (MCC) is an aggressive skin cancer that is typically caused in part by the recently discovered Merkel cell polyomavirus (MCPyV). T lymphocytes are unusually important for survival in this cancer. In a phase I/II trial, we will combine approaches that reverse local immune evasion mechanisms with infusion of polyclonal MCPyV-specific T cells. Reagents and insights from the proposed studies will also facilitate future therapies that use recombinant T cell receptors specific for MCPyV.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Song, Min-Kyung H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Becker, Jürgen C; Stang, Andreas; Hausen, Axel Zur et al. (2018) Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunol Immunother 67:341-351
Paulson, Kelly G; Park, Song Youn; Vandeven, Natalie A et al. (2018) Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78:457-463.e2
Becker, Jürgen C; Stang, Andreas; DeCaprio, James A et al. (2017) Merkel cell carcinoma. Nat Rev Dis Primers 3:17077
Miller, Natalie J; Church, Candice D; Dong, Lichun et al. (2017) Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res 5:137-147
Moshiri, Ata S; Doumani, Ryan; Yelistratova, Lola et al. (2017) Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. J Invest Dermatol 137:819-827
Paulson, Kelly G; Lewis, Christopher W; Redman, Mary W et al. (2017) Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer 123:1464-1474
Goh, Gerald; Walradt, Trent; Markarov, Vladimir et al. (2016) Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7:3403-15
Iyer, Jayasri G; Blom, Astrid; Doumani, Ryan et al. (2016) Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 5:2294-301
Church, Candice D; Nghiem, Paul (2015) How does the Merkel polyomavirus lead to a lethal cancer? Many answers, many questions, and a new mouse model. J Invest Dermatol 135:1221-1224

Showing the most recent 10 out of 21 publications